APERTO becomes the first drug-coated balloon to be approved in China for the treatment of AVF stenosis


APERTOAPERTO, Cardionovum’s paclitaxel-coated balloon for arterio-venous access, has received market approval for China, making it the first high pressure drug-coated balloon (DCB) available in China to treat obstructive lesions of native arterio-venous dialysis fistulae (AVF).

The approval was given based on the statistical superiority shown in a clinical study in Chinese populations: APERTO AVF RCT CHINA.

This is the first AVF randomised controlled study to archive statistical superiority of a high pressure DCB versus high-pressure plain balloon angioplasty. In a population of 161 patients, treatment with the device achieved superiority in freedom from restenosis at six months, and better intervention-free survival of both the target lesion and target shunt at 12 months with equivalent safety. Additionally, patients treated with APERTO maintained patency for another three months.


Please enter your comment!
Please enter your name here